Yolanda MarÃ-a Pacheco

List of Publications by Year
in descending order

78 papers	1,754 citations	257450 24 h-index	315739 38 g-index
79 all docs	79 docs citations	79 times ranked	2653 citing authors

#	Article	IF	Citations
1	Gal3 Plays a Deleterious Role in a Mouse Model of Endotoxemia. International Journal of Molecular Sciences, 2022, 23, 1170.	4.1	3
2	Partial restoration of gutâ€mucosal dysbiosis in lateâ€treated HIVâ€infected subjects with CD4 Tâ€cell recovery. Clinical and Translational Medicine, 2022, 12, e788.	4.0	4
3	Oleic acidâ€"the main component of olive oil on postprandial metabolic processes. , 2021, , 639-649.		2
4	Immunological features beyond CD4/CD8 ratio values in older individuals. Aging, 2021, 13, 13443-13459.	3.1	20
5	DBP rs7041 and DHCR7 rs3829251 are Linked to CD4+ Recovery in HIV Patients on Antiretroviral Therapy. Frontiers in Pharmacology, 2021, 12, 773848.	3.5	0
6	High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. EBioMedicine, 2020, 62, 103077.	6.1	15
7	Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects. Frontiers in Immunology, 2020, 11, 581307.	4.8	6
8	New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144. Scientific Reports, 2020, 10, 2937.	3.3	14
9	CD4 recovery is associated with genetic variation in IFNÎ³ and IL19 genes. Antiviral Research, 2019, 170, 104577.	4.1	7
10	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. Scientific Reports, 2019, 9, 15722.	3.3	4
11	IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. Biomolecules, 2019, 9, 233.	4.0	9
12	Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. Clinical Science, 2019, 133, 997-1010.	4.3	21
13	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression. PLoS ONE, 2019, 14, e0214421.	2.5	11
14	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2019, , 1865-1882.		0
15	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. Atherosclerosis, 2018, 273, 28-36.	0.8	15
16	An in vitro system of autologous lymphocytes culture that allows the study of homeostatic proliferation mechanisms in human naive CD4 T-cells. Laboratory Investigation, 2018, 98, 500-511.	3.7	11
17	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. Aids, 2018, 32, 565-573.	2.2	26
18	Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4

#	Article	IF	Citations
19	Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment. Journal of Infection, 2018, 76, 86-92.	3.3	9
20	Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy. Journal of Translational Medicine, 2018, 16, 343.	4.4	6
21	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2018, , 1-18.		0
22	Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination. Journal of Translational Medicine, 2018, 16, 238.	4.4	5
23	HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and Î±4Î²7 on CD4 T-Cells Prior Therapy Initiation. Frontiers in Immunology, 2018, 9, 1673.	4.8	7
24	A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
25	Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery. Antiviral Research, 2017, 142, 76-82.	4.1	22
26	Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects. Clinical Infectious Diseases, 2017, 64, 152-158.	5.8	26
27	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	5.8	30
28	CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. Thrombosis and Haemostasis, 2017, 117, 1141-1149.	3.4	9
29	Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients. Viral Immunology, 2016, 29, 471-477.	1.3	7
30	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 6398-6401.	3.2	0
31	Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects. Clinical Microbiology and Infection, 2016, 22, 461.e1-461.e5.	6.0	10
32	Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 610-618.	3.6	33
33	Phenotype and Polyfunctional Deregulation Involving Interleukin 6 (IL-6)â€“ and IL-10â€“Producing Monocytes in HIV-Infected Patients Receiving Combination Antiretroviral Therapy Differ From Those in Healthy Older Individuals. Journal of Infectious Diseases, 2016, 213, 999-1007.	4.0	14
34	Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Research, 2015, 117, 69-74.	4.1	69
35	Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naÃ¯ve HIV-infected patients. Antiviral Research, 2015, 121, 94-96.	4.1	5
36	Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 81-101.	3.3	10

#	Article	IF	Citations
37	Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects. Journal of Infectious Diseases, 2014, 210, 890-898.	4.0	23
38	HIV Infection Deregulates the Balance Between Regulatory T Cells and IL-2â€“Producing CD4 T Cells by Decreasing the Expression of the IL-2 Receptor in Treg. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 278-282.	2.1	15
39	Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. Clinical Microbiology and Infection, 2013, 19, 558-565.	6.0	23
40	Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14. Journal of Infectious Diseases, 2013, 207, 1221-1225.	4.0	69
41	Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. Journal of Antimicrobial Chemotherapy, 2012, 67, 1228-1237.	3.0	29
42	Mendez-Lagares et al (J Infect Dis 2012; 205:1501-9). Journal of Infectious Diseases, 2012, 206, 1951-1951.	4.0	0
43	Detectable Viral Load Aggravates Immunosenescence Features of CD8 T-Cell Subsets in Vertically HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 447-454.	2.1	20
44	Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers. Journal of Infection, 2012, 65, 431-438.	3.3	41
45	Triglyceride-Rich Lipoprotein Regulates APOB48 Receptor Gene Expression in Human THP-1 Monocytes and Macrophages3. Journal of Nutrition, 2012, 142, 227-232.	2.9	22
46	Severe Immune Dysregulation Affects CD4+CD25hiFoxP3+ Regulatory T Cells in HIV-Infected Patients With Low-level CD4 T-Cell Repopulation Despite Suppressive Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2012, 205, 1501-1509.	4.0	59
47	Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. Antiviral Research, 2012, 95, 207-211.	4.1	6
48	Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-Î². Experimental Cell Research, 2011, 317, 131-142.	2.6	11
49	Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. American Journal of Clinical Nutrition, 2011, 93, 494-499.	4.7	90
50	A high-fat meal promotes lipid-load and apolipoprotein B-48 receptor transcriptional activity in circulating monocytes. American Journal of Clinical Nutrition, 2011, 93, 918-925.	4.7	43
51	Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective. Current Pharmaceutical Design, 2011, 17, 831-843.	1.9	79
52	Is it age or HIV that drives the regulatory T-cells expansion that occurs in older HIV-infected persons?. Clinical Immunology, 2010, 136, 157-159.	3.2	6
53	CD4+CD25+/hiCD127loPhenotype Does Not Accurately Identify Regulatory T Cells in All Populations of HIVâ€Infected Persons. Journal of Infectious Diseases, 2010, 201, 331-335.	4.0	37
54	Increased Regulatory T Cell Counts in HIVâ€Infected Nonresponders to Hepatitis B Virus Vaccine. Journal of Infectious Diseases, 2010, 202, 362-369.	4.0	39

#	Article	IF	Citations
55	Oleic Acid. , 2010, , 1385-1393.		6
56	The TLR4 ASP299GLY Polymorphism is a Risk Factor for Active Tuberculosis in Caucasian HIV-Infected Patients. Current HIV Research, 2010, 8, 253-258.	0.5	38
57	High Levels of CD57+CD28- T-Cells, Low T-Cell Proliferation and Preferential Expansion of Terminally Differentiated CD4+ T-Cells in HIVElite Controllers. Current HIV Research, 2010, 8, 471-481.	0.5	15
58	Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART. Current HIV Research, 2009, 7, 612-619.	0.5	26
59	A meal rich in oleic acid beneficially modulates postprandial sICAM-1 and sVCAM-1 in normotensive and hypertensive hypertriglyceridemic subjects. Journal of Nutritional Biochemistry, 2008, 19, 200-205.	4.2	60
60	Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovascular Research, 2008, 79, 294-303.	3.8	68
61	Distinctive postprandial modulation of Î² cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. American Journal of Clinical Nutrition, 2008, 88, 638-644.	4.7	138
62	Minor compounds of olive oil have postprandial anti-inflammatory effects. British Journal of Nutrition, 2007, 98, 260-263.	2.3	46
63	Dietary Oleic and Palmitic Acids Modulate the Ratio of Triacylglycerols to Cholesterol in Postprandial Triacylglycerol-Rich Lipoproteins in Men and Cell Viability and Cycling in Human Monocytes3. Journal of Nutrition, 2007, 137, 1999-2005.	2.9	17
64	Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men. American Journal of Clinical Nutrition, 2006, 84, 342-349.	4.7	44
65	Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men1â€“4. American Journal of Clinical Nutrition, 2006, 84, 342-349.	4.7	48
66	Extra-virgin vs. refined olive oil on postprandial hemostatic markers in healthy subjects. Journal of Thrombosis and Haemostasis, 2006, 4, 1421-1422.	3.8	29
67	Postprandial evolution of the carotenoid content in the triacylglycerol-rich lipoprotein fraction after a single ingestion of virgin olive oil in humans. Food Research International, 2005, 38, 1097-1102.	6.2	9
68	Dietary virgin olive oil triacylglycerols as an independent determinant of very low-density lipoprotein composition. Nutrition, 2004, 20, 509-514.	2.4	8
69	Olive oil and cancer. Grasas Y Aceites, 2004, 55, .	0.9	1
70	Blood transport and genomic effects of olive oil components. Grasas Y Aceites, 2004, 55, .	0.9	0
71	Digestion and absorption of olive oil. Grasas Y Aceites, 2004, 55, .	0.9	1
72	Sphingosine 1-phosphate signal survival and mitogenesis are mediated by lipid-stereospecific binding of triacylglycerol-rich lipoproteins. Cellular and Molecular Life Sciences, 2003, 60, 2757-2766.	5.4	6

#	Article	IF	Citations
73	Distribution of fatty acids from dietary oils into phospholipid classes of triacylglycerol-rich lipoproteins in healthy subjects. Life Sciences, 2003, 72, 1643-1654.	4.3	10
74	Triacylglycerol-rich lipoproteins trigger the phosphorylation of extracellular-signal regulated kinases in vascular cells. Life Sciences, 2002, 71, 1351-1360.	4.3	3
75	Triacylglycerol-Rich Lipoproteins Interact with Human Vascular Cells in a Lipid-Dependent Fashion. Journal of Agricultural and Food Chemistry, 2001, 49, 5653-5661.	5.2	10
76	The Metabolic Availability of Dietary Triacylglycerols from Two High Oleic Oils during the Postprandial Period Does Not Depend on the Amount of Oleic Acid Ingested by Healthy Men. Journal of Nutrition, 2001, 131, 59-65.	2.9	56
77	Postprandial Triacylglycerols from Dietary Virgin Olive Oil Are Selectively Cleared in Humans. Journal of Nutrition, 1999, 129, 2184-2191.	2.9	31
78	Incorporation of dietary triacylglycerols from olive oil and high-oleic sunflower oil into VLDL triacylglycerols of hypertensive patients. European Journal of Clinical Nutrition, 1999, 53, 687-693.	2.9	21